Research.Patient.info
and combination treatment will also be evaluated with nivolumab in NSCLC research hub
2 indexed studies · 0 currently recruiting
- ongoing, recruitingHuman Pharmacology (Phase I)- Other
A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors
This study is testing a new medicine, XB002, for people with advanced cancers that can't be operated on or when current treatments aren't working. It will look at how safe the medicine is, how it moves through the body, and if it works alone or with other cancer drugs.
Netherlands · Spain · Belgium - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase I Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus TILT-123 in combination with avelumab in injectable solid tumor patients (melanoma and SCCHN) refractory to or progressing after anti-PD(L)1 immunotherapy
This study is testing a new treatment, TILT-123 with avelumab, for certain skin cancers (melanoma) and head and neck cancers that haven't responded well to other treatments. It's an early-stage trial looking at safety and finding the right dose.
Finland